Physician profile
John Anton
NPI 1780603613
$10,270.04
in general payments reported to CMS, 2019-2025
46 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,800 · 2020: $1,785 · 2021: $1,642 · 2022: $730 · 2023: $1,310 · 2024: $1,527 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,311.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,073.26 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Acadia Pharmaceuticals INC | $1,040.50 | 2020-2025 | Nuplazid |
| Amarin Pharma, INC. | $907.67 | 2019-2022 | |
| Abbvie INC. | $724.94 | 2023-2025 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $683.68 | 2019-2024 | Farxiga |
| Integra Lifesciences Corporation | $665.09 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $514.18 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $467.61 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $344.24 | 2020-2024 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $328.76 | 2019-2025 | |
| Allergan, INC. | $279.52 | 2019 | |
| Janssen Pharmaceuticals, INC | $275.42 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $261.80 | 2019-2021 | |
| Aytu Biopharma, INC. | $256.35 | 2019-2020 | |
| Amgen INC. | $255.04 | 2019-2025 | Repatha, Repatha |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.17 | 2020-2025 | Jardiance |
| Boston Scientific Corporation | $147.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $146.71 | 2020-2024 | Eliquis, Camzyos |
| Kowa Pharmaceuticals America, INC. | $139.18 | 2019-2022 | |
| Ibsa Pharma INC. | $135.74 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $124.28 | 2021 | |
| Eisai INC. | $123.07 | 2019-2021 | |
| Horizon Therapeutics Plc | $119.73 | 2020-2022 | |
| Shionogi INC | $117.68 | 2022 | |
| Idorsia Pharmaceuticals US INC | $115.19 | 2022-2023 | Quviviq |
| Smith+Nephew, INC. | $107.34 | 2019 | |
| Csl Behring | $104.37 | 2024 | Kcentra |
| Esperion Therapeutics, INC. | $99.92 | 2020-2024 | Nexletol |
| Abbott Laboratories | $86.52 | 2021-2023 | Freestyle Libre 3 |
| Lundbeck LLC | $60.50 | 2019-2024 | Rexulti |
| Hikma Pharmaceuticals USA | $43.97 | 2021-2022 | |
| Althera Pharmaceuticals LLC | $31.16 | 2021-2022 | |
| Insmed, INC. | $31.00 | 2024 | Arikayce |
| Lilly USA, LLC | $30.84 | 2024-2025 | Zepbound |
| Ani Pharmaceuticals, INC. | $30.29 | 2024 | Purified Cortrophin Gel |
| Neos Therapeutics, Lp | $23.58 | 2021 | |
| Dexcom, INC. | $22.51 | 2022 | |
| Edwards Lifesciences Corporation | $19.83 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kci USA, INC. | $16.17 | 2022 | |
| Currax Pharmaceuticals LLC | $16.17 | 2025 | Contrave |
| Gilead Sciences, INC. | $15.79 | 2024 | |
| Neurelis, INC. | $15.00 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.56 | 2019 | |
| Philips North America LLC | $14.41 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.60 | 2021 | |
| Medtronic USA, INC. | $11.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Anton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.